01 1Tafinlar
02 9Tafinlar/Mekinist
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,542
2019 Revenue in Millions : 1,338
Growth (%) : 15
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,693
2020 Revenue in Millions : 1,542
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,770
2021 Revenue in Millions : 1,693
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,922
2022 Revenue in Millions : 1,770
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 743.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 453
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 672
2015 Revenue in Millions : 453
Growth (%) : 48
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 873
2016 Revenue in Millions : 672
Growth (%) : 30
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,155
2017 Revenue in Millions : 873
Growth (%) : 32%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,338
2018 Revenue in Millions : 1,155
Growth (%) : 16
LOOKING FOR A SUPPLIER?